For these reasons, MSLN has been gaining momentum in recent years, leading to the emergence of a variety of targeted therapeutic approaches at various stages of development, including antibody-based therapies (ADC or immunotherapy), vaccine or cellular (CAR-T cells) approaches (6–8), mainly for malignant mesothelioma and ovarian cancer indications. The gene discussed is MSLN; the disease is ovarian cancer.